Akums Drugs and Pharmaceuticals IPO Details: The Akums Drugs and Pharmaceuticals IPO is set to open on July 30, 2024, and will close on August 1, 2024. Through this IPO, Akums aims to raise approximately ₹1,856.74 crores, which includes a fresh issue of ₹680.00 crores and an offer for sale of up to 17,330,435 equity shares at ₹2 each. The allocation for this IPO includes a 10% retail quota, 75% for Qualified Institutional Buyers (QIB), and 15% for High Net Worth Individuals (HNI).
Founded in 2004, Akums Drugs and Pharmaceuticals has established itself as a leading pharmaceutical contract development and manufacturing organization (CDMO) in India and internationally. They are renowned for owning intellectual property rights for various manufacturing processes and specialize in providing comprehensive product development and manufacturing solutions. Their offerings also encompass formulation research and development (R&D), regulatory dossier preparation, and testing services for both Indian and global markets. Besides their core CDMO operations, Akums is involved in manufacturing and selling branded pharmaceutical formulations and active pharmaceutical ingredients (APIs).
Akums is recognized as the largest India-focused CDMO in terms of revenue, production capacity, and client base for the fiscal year 2023, as reported by Frost & Sullivan (F&S Report). They manufacture a diverse range of dosage forms, including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies. In the fiscal year 2024, they held a 30.2% share of the Indian domestic CDMO market by value, up from 26.7% in fiscal year 2021, according to the F&S Report.
Akums Drugs and Pharmaceuticals IPO Objectives:
The Company proposes to utilize the Net Proceeds towards the funding of the following objects:
- Repayment/ prepayment of indebtedness of the company and its Subsidiaries;
- Funding incremental working capital requirements of the company;
- Pursuing inorganic growth initiatives through acquisitions; and
- General corporate purposes.
Akums Drugs and Pharmaceuticals IPO Review (Apply or Not)
- Update soon.
Akums Drugs and Pharmaceuticals IPO Date & Price Band Details:
| IPO Open: | July 30, 2024 |
| IPO Close: | August 1, 2024 |
| IPO Size: | Approx ₹1856.74 Crores, 27,345,162 Equity Share |
| Fresh Issue: | Approx ₹680.00 Crores, 10,014,727 Equity Share |
| Offer for Sale: | Approx ₹1262.83 Crores, 17,330,435 Equity Share |
| Face Value: | ₹2 Per Equity Share |
| IPO Price Band: | ₹646 to ₹679 Per Share |
| IPO Listing on: | BSE & NSE |
| Retail Quota: | 10% |
| QIB Quota: | 75% |
| NII Quota: | 15% |
| Discount: | N/A |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Akums Drugs and Pharmaceuticals IPO Lot Size:
The minimum market lot for the Akums Drugs and Pharmaceuticals IPO consists of 22 shares, requiring an application amount of ₹14,938. Retail investors have the option to apply for up to 13 lots, totaling 286 shares, which amounts to ₹194,194.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 22 | ₹14,938 |
| Retail Maximum | 13 | 286 | ₹194,194 |
| S-HNI Minimum | 14 | 308 | ₹209,132 |
| B-HNI Minimum | 67 | 1474 | ₹1,000,846 |
Akums Drugs and Pharmaceuticals IPO Timeline:
The Akums Drugs and Pharmaceuticals IPO will open on July 30 and close on August 1. The allotment of shares is scheduled to be finalized on August 2, with the IPO listing expected on August 6.
| IPO Open Date: | July 30, 2024 |
| IPO Close Date: | August 1, 2024 |
| Basis of Allotment: | August 2, 2024 |
| Refunds: | August 5, 2024 |
| Credit to Demat Account: | August 5, 2024 |
| IPO Listing Date: | August 6, 2024 |
Akums Drugs and Pharmaceuticals IPO GMP Today:
The latest Grey Market Premium (GMP) for the Akums Drugs and Pharmaceuticals IPO is ₹155. With a price band of ₹679.00, the estimated listing price is projected to be ₹834, calculated as the cap price plus today’s GMP. This translates to an expected gain of 22.83% per share.
Akums Drugs and Pharmaceuticals Company Financial Report
| ₹ in Crores | |||
| Year | Revenue | Expense | PAT |
| 2022 | ₹3694.52 | ₹3874.95 | ₹250.87 |
| 2023 | ₹3700.93 | ₹3475.93 | ₹97.82 |
| 2024 | ₹4212.21 | ₹4231.45 | ₹0.79 |
Akums Drugs and Pharmaceuticals IPO Valuation – FY2024
Check Akums Drugs and Pharmaceuticals IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| Earning Per Share (EPS): | ₹-0.28 per Equity Share |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | -0.57% |
| Net Asset Value (NAV): | ₹49.59 per Equity Share |
Peer Group
- Divi’s Laboratories
- Suven Pharma
- Gland Pharma
- Torrent Pharma
- Alkem Laboratories
- Eris Lifesciences
- JB Chemicals
- Mankind Pharma
- Innova Captab
Company Promoters
- Sanjeev Jain
- Sandeep Jain
- Akums Master Trust
Akums Drugs and Pharmaceuticals IPO Registrar
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: Signatureglobal.ipo@linkintime.co.in
Website: https://linkintime.co.in/
Akums Drugs and Pharmaceuticals IPO Allotment Status Check
Check Akums Drugs and Pharmaceuticals IPO allotment status on Linkintime website allotment URL. Click Here
Akums Drugs and Pharmaceuticals IPO Lead Managers aka Merchant Bankers
- ICICI Securities Limited
- Axis Bank Limited
- Citigroup Global Markets India Private Limited
- Ambit Private Limited
Company Address
Akums Drugs and Pharmaceuticals Limited
304, Mohan Place,
LSC Saraswati Vihar,
Delhi – 110 034
Phone: +91 11 6904 1000
Email: cs@akums.net
Website: http://www.akums.in/
Akums Drugs and Pharmaceuticals IPO FAQs
1. What are the dates for the Akums Drugs and Pharmaceuticals IPO?
The IPO will open on July 30, 2024, and close on August 1, 2024. The allotment of shares is expected to be finalized on August 2, 2024, and the shares are scheduled to be listed on August 6, 2024.
2. What is the price band for the Akums Drugs and Pharmaceuticals IPO?
The price band for the IPO is set at ₹679.00 per share.
3. How many shares can retail investors apply for in the Akums Drugs and Pharmaceuticals IPO?
Retail investors can apply for a minimum market lot of 22 shares, with an application amount of ₹14,938. They can apply for up to 13 lots, totaling 286 shares, amounting to ₹194,194.
4. What is the purpose of the Akums Drugs and Pharmaceuticals IPO?
The IPO aims to raise approximately ₹1,856.74 crores. This includes a fresh issue of ₹680.00 crores and an offer for sale of up to 17,330,435 equity shares. The funds will be used for corporate purposes, including debt repayment, capital expenditure, and expansion plans.
5. What is the Grey Market Premium (GMP) for the Akums Drugs and Pharmaceuticals IPO?
As of July 25, 2024, the latest GMP is ₹155. This GMP can fluctuate based on market conditions and investor sentiment.
6. How is the estimated listing price for the Akums Drugs and Pharmaceuticals IPO calculated?
The estimated listing price is calculated by adding the GMP to the cap price of the IPO. Based on the current GMP of ₹155 and the cap price of ₹679.00, the estimated listing price is ₹834.
7. What are the expected gains or losses per share for the Akums Drugs and Pharmaceuticals IPO?
The expected percentage gain per share is approximately 22.83%, based on the current GMP and price band.
8. What are the investor quotas for the Akums Drugs and Pharmaceuticals IPO?
The IPO allocation includes a 10% quota for retail investors, 75% for Qualified Institutional Buyers (QIBs), and 15% for High Net Worth Individuals (HNIs).
9. How can I apply for the Akums Drugs and Pharmaceuticals IPO?
You can apply for the IPO through your bank or brokerage platform using the ASBA (Application Supported by Blocked Amount) facility. Make sure to have a Demat account to receive the allotted shares.
10. Who are Akums Drugs and Pharmaceuticals, and what do they do?
Founded in 2004, Akums Drugs and Pharmaceuticals is a leading pharmaceutical contract development and manufacturing organization (CDMO) in India. They specialize in product development, manufacturing solutions, and regulatory services, and are also involved in the sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs).
